MeiraGTx, a New York and London-based company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders.
We are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). We are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. Our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
We are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). We are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. Our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
Location: United States, New York
Total raised: $175M
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.08.2022 | - | $100M | Perceptive... |
| 24.07.2018 | IPO | $75M | - |
Mentions in press and media 16
| Date | Title | Description |
| 25.11.2024 | Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors | ROCKVILLE, Md. and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily ... |
| 12.08.2024 | Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights | SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the... |
| 12.08.2024 | Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights | SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the... |
| 09.03.2024 | OpenAI announces 'improvements' to its governance structure nearly 5 months after Sam Altman's ouster | Tech OpenAI announces 'improvements' to its governance structure nearly 5 months after Sam Altman's ouster Erin Snodgrass and Lloyd Lee 2024-03-09T03:30:42Z Share icon An curved arrow pointing right. Share Facebook Icon The letter F. Facebo... |
| 21.12.2023 | MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million | - |
| 30.10.2023 | MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities | - |
| 01.10.2022 | Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigm... | LONDON and NEW YORK, Oct. 01, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc MGTX, a vertically integrated, clinical-stage gene therapy company, announced today the primary results from the Phase 1/2 study evaluating the investigational gen... |
| 16.09.2022 | MeiraGTx unveils bioscience manufacturing site in Shannon | Ireland’s first commercial-scale gene therapy manufacturing site, operated by MeiraGTx, was unveiled today in a ceremony attended by Taoiseach Micheál Martin in Shannon. The 150,000 sq ft facility develops curative treatments for illnesses ... |
| 03.08.2022 | MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities | - Credit facility is collateralized by MeiraGTx’s wholly-owned manufacturing facilities in London, UK and Shannon, Ireland - $75 million at closing strengthens balance sheet and extends runway to fourth quarter of 2024 LONDON and NEW YORK, ... |
| 27.01.2022 | MeiraGTx Gets $30 Million Milestone Payment From Janssen Pharmaceuticals | By Chris Wack MeiraGTx Holdings PLC said it received a $30 million payment from Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Cos. of Johnson & Johnson, for a clinical milestone in a Phase 3 trial of botaretigene spar... |
Show more